Insilico Medicine Inc. has prepared and tested new spirocyclic mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1) inhibitors reported to be useful for the treatment of cancer and viral infections.
Fermitin family homolog 1 (FERMT1), a member of the kindlin family of focal adhesion proteins, plays a pivotal role in mediating integrin-dependent cell adhesion and signaling. Scientists at Fujian Medical University (FJMU) assessed the functional significance of FERMT1 in glioma progression and stemness.
Researchers from Edgewise Therapeutics Inc. presented preclinical data for the cardiac sarcomere modulator, EDG-7500, which is being developed for the treatment of hypertrophic cardiomyopathy (HCM) and other diseases of diastolic dysfunction.
G protein-coupled receptor (GPCR) drug discovery and development specialist Confo Therapeutics NV has closed a €60 million (US$65.2 million) series B round that will fund a significant expansion of the inhouse portfolio while it continues to turn the handle on its technology platform to generate more compounds for partnering.
Researchers from Universite de Sherbrooke and University of California San Francisco presented the discovery and preclinical characterization of CCR2-targeting pepducin, PP-101.
Researchers from Qingdao University and affiliated organizations announced data from a preclinical study using the phosphodiesterase 7 (PDE7) inhibitor BRL-50481 to assess the involvement of PDE7 in the stress-induced behavioral and neuron morphological changes.
Researchers from the University of Pennsylvania have successfully inhibited vasohibin enzymes (VASH) with SVC-01 and SVC-02 in the ZSF1 obese rat model of heart failure with preserved ejection fraction (HFpEF).
Camptothecin derivatives reported to be useful for the treatment of cancer have been disclosed in a recent Genescience Pharmaceuticals Co. Ltd. patent.
RSS
